Associazione Nazionale Medici Cardiologi Ospedalieri

www.anmco.it

CONGRESS ABSTRACT

CONGRESS ABSTRACT

Categorie
STATIN INTOLERANCE IN A REAL WORD SETTING OF ITALIAN CARDIOLOGY CENTERS: DATA FROM THE BRING-UP PREVENTION STUDY
Anno:
2025
Background. Statins are commonly prescribed to prevent cardiovascular disease by lowering low-density lipoprotein cholesterol (LDL-C). However, statin intolerance can limit their use or adherence to optimal high-intensity statin therapy. Observational studies have estimated intolerance in 25-30% of patients, while the prevalence in randomised clinical trials has been largely lower….
Leggi di più
SECONDARY PREVENTION IN PATIENTS AT EXTREME CARDIOVASCULAR RISK: WHAT CAN WE DO MORE?
Anno:
2025
Prevalence of Heterozygous Familial Hypercholesterolemia (FH) is estimated to be around 1/200-250, which corresponds to 14-34 million cases worldwide. A 27 years-old man was referred to our clinic because of exercise angina. He had a total cholesterol (TC) of 379 mg/dl, HDL 38 mg/dl, LDL 330 mg/dl and TG…
Leggi di più
The future of lowering triglycerides therapy in secondary cardiovascular prevention: insights from the JET-LDL Registry
Anno:
2025
Rational Hypertriglyceridemia is a common finding in patients with coronary artery disease (CAD), contributing to the residual cardiovascular risk in this population. In CAD patients with persistently elevated triglycerides levels despite lipid lowering therapies, a treatment with icosapent ethyl (IPE), compared to placebo, significantly lowered the risk of ischemic…
Leggi di più
EFFECTIVENESS OF RENAL DENERVATION IN HIGH RISK PATIENTS WITH RESISTANT HYPERTENSION
Anno:
2025
Background: Recent trials have confirmed the safety and efficacy of catheter-based renal denervation (RDN) as nonpharmacological treatment in resistant hypertension  in the presence of concomitant antihypertensive therapy. Aim: we report data of preliminary experience with RDN (Symplicity Spyral renal denervation system, Medtronic Inc.) in patients with resistant hypertension and…
Leggi di più
TO IMPROVE THE QUALITY OF SECONDARY PREVENTION STRATEGIES IN DIABETIC PATIENTS: THE BRING-UP PREVENTION STUDY RESULTS
Anno:
2025
Background. Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in people with diabetes, making secondary prevention strategies critical to improving patient outcomes. Purpose. To try to narrow the gap between what is recommended by the current guidelines and what is implemented in clinical practice in diabetic…
Leggi di più
USE OF BEMPEDOIC ACID IN CLINICAL PRACTICE IN CAMPANIA: PRELIMINARY RESULTS OF THE BEACON STUDY (BEMPEDOIC ACID IN CAMPANIA: OPTIMIZING NEED) INTRODUCTION
Anno:
2025
Background: The aim of the present study was to evaluate the profile of patients prescribed Bempedoic acid (BA) in outpatient clinical practice in the Campania Region; in addition, the efficacy, tolerability of the drug and therapeutic adherence in short-term follow-up were assessed. Methods: The BeACON (Bempedoic Acid in Campania:…
Leggi di più
EFFICACY AND SAFETY OF INCLISIRAN IN OUTPATIENTS WITH RECENT ACUTE CORONARY SYNDROME.
Anno:
2025
Background: Early and intensive low-density lipoprotein cholesterol (LDL-C) reduction after recent acute coronary syndrome (ACS) may reduce recurrent CV event risk. Aim: To evaluate the efficacy in LDL-C lowering added to usual care, of inclisiran administrated in outpatient with recent ACS. Methods: The routine data of 11 patients (8 M/3 F)…
Leggi di più
The challenge of secondary cardiovascular prevention in very high Lipoprotein (a) level. A case report
Anno:
2025
Background While advances in technology and procedural techniques have significantly improved outcomes post-PCI, two pharmacological strategies have gained particular attention for their effectiveness in reducing long-term cardiovascular (CV) risk: antiplatelet therapies and lipid-lowering therapies (LLT). The 10-year recurrence risk for major CV events remains as high as 10–30%, due…
Leggi di più
Polypharmacy and acute kidney function impairment after starting bempedoic acid
Anno:
2025
Background. Bempedoic acid is an established treatment for dyslipidemia. In randomized clinical trial the treatment with bempedoic acid was associated with a small increase in creatinine levels. We present the  case of a patient with chronic coronary syndrome, heart failure with mild reduction of ejection fraction, and dyslipidemia with…
Leggi di più
TRIPLE ORAL COMBINATION TO LOWER LDL-C IN A PATIENT WITH POLYVASCULAR DISEASES
Anno:
2025
Patients with Peripheral Artery Disease are at increased risk of atherosclerotic cardiovascular (CV) events with high rate of recurrence. Bempedoic acid is a therapeutical option for the management of patients with hypercholesterolemia approved by EMA in 2020 and available in Italy since 2023.   We report the case of…
Leggi di più

A.N.M.C.O. – Via La Marmora 36, 50121 Firenze (Italy) – Partita I.V.A. 05469530488 – Codice Fiscale 01301130488 – Privacy
www.anmco.it | segreteria@anmco.it

Cookie Policy Privacy Policy

Seguici su

Facebook Twitter Youtube Linkedin Instagram Telegram